

Amendments to the Claims:

Per 37 C.F.R. §1.121, the current status of all the claims in the present application is presented below, amended claims are notated to indicate changes made and the text of pending claims not being amended are presented without notation. Amendments to the following are indicated by underlining what has been added and striking-through what has been deleted.

Listing of Claims:

1. (currently amended) A fusion protein comprising a first polypeptide comprising a sequence of amino acid residues that is at least 90% identical to residues 41 to 148 of SEQ ID NO:2 and comprising a second ~~cytokine~~ IL-2 polypeptide as shown in SEQ ID NO:111 or fragment thereof, wherein the fusion protein binds a receptor as shown in SEQ ID NO:115.

2. (canceled)

3-9. (canceled).

10. (currently amended) The fusion protein of claim 1, wherein the first polypeptide of at least 95% identical to residues 41 to 148 of ~~identity to a sequence of amino acid residues as shown in~~ SEQ ID NO:2.

11. (currently amended) The fusion protein of claim 1, wherein the first polypeptide comprises residues 41 to 148 of ~~is the sequence of amino acid residues as shown in~~ SEQ ID NO:2 and ~~wherein the second polypeptide is IL-2 as shown in~~ SEQ ID NO:111.

12. (canceled)

13. (new) A fusion protein comprising a first polypeptide comprising amino acid residues 32 to 162 of SEQ ID NO:2 and comprising a second IL-2 polypeptide as shown in SEQ ID NO:111 or fragment thereof, wherein the fusion protein binds a receptor as shown in SEQ ID NO:115.